Recalcitrant Dermatomyositis Treated With Anifrolumab
Dermatomyositis is an idiopathic inflammatory myopathy which can present with distinctive skin features. Despite the many treatment modalities for the treatment of dermatomyositis some patients remain refractory to treatment. We present a case of a 38‐year‐old man with recalcitrant dermatomyositis w...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | ACR Open Rheumatology |
| Online Access: | https://doi.org/10.1002/acr2.11792 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832542403174596608 |
|---|---|
| author | Shivang Chaudhary Meghan Baumer Laura Upton Samantha Ong Kristin Smith Daniel West Adam Kilian |
| author_facet | Shivang Chaudhary Meghan Baumer Laura Upton Samantha Ong Kristin Smith Daniel West Adam Kilian |
| author_sort | Shivang Chaudhary |
| collection | DOAJ |
| description | Dermatomyositis is an idiopathic inflammatory myopathy which can present with distinctive skin features. Despite the many treatment modalities for the treatment of dermatomyositis some patients remain refractory to treatment. We present a case of a 38‐year‐old man with recalcitrant dermatomyositis who was successfully treated with the interferon α receptor 1‐inhibiting monoclonal antibody anifrolumab. Many studies have shown a correlation between dermatomyositis disease activity and the type 1 interferon pathway activity. We believe anifrolumab may be a promising option for severe cutaneous dermatomyositis. |
| format | Article |
| id | doaj-art-c57d7f7a1b9e4243a0d05715567d2caf |
| institution | Kabale University |
| issn | 2578-5745 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | ACR Open Rheumatology |
| spelling | doaj-art-c57d7f7a1b9e4243a0d05715567d2caf2025-02-04T06:21:22ZengWileyACR Open Rheumatology2578-57452025-01-0171n/an/a10.1002/acr2.11792Recalcitrant Dermatomyositis Treated With AnifrolumabShivang Chaudhary0Meghan Baumer1Laura Upton2Samantha Ong3Kristin Smith4Daniel West5Adam Kilian6Saint Louis University School of Medicine St. Louis MissouriSaint Louis University School of Medicine St. Louis MissouriSaint Louis University School of Medicine St. Louis MissouriSaint Louis University School of Medicine St. Louis MissouriSaint Louis University School of Medicine St. Louis MissouriSaint Louis University School of Medicine St. Louis MissouriSaint Louis University School of Medicine St. Louis MissouriDermatomyositis is an idiopathic inflammatory myopathy which can present with distinctive skin features. Despite the many treatment modalities for the treatment of dermatomyositis some patients remain refractory to treatment. We present a case of a 38‐year‐old man with recalcitrant dermatomyositis who was successfully treated with the interferon α receptor 1‐inhibiting monoclonal antibody anifrolumab. Many studies have shown a correlation between dermatomyositis disease activity and the type 1 interferon pathway activity. We believe anifrolumab may be a promising option for severe cutaneous dermatomyositis.https://doi.org/10.1002/acr2.11792 |
| spellingShingle | Shivang Chaudhary Meghan Baumer Laura Upton Samantha Ong Kristin Smith Daniel West Adam Kilian Recalcitrant Dermatomyositis Treated With Anifrolumab ACR Open Rheumatology |
| title | Recalcitrant Dermatomyositis Treated With Anifrolumab |
| title_full | Recalcitrant Dermatomyositis Treated With Anifrolumab |
| title_fullStr | Recalcitrant Dermatomyositis Treated With Anifrolumab |
| title_full_unstemmed | Recalcitrant Dermatomyositis Treated With Anifrolumab |
| title_short | Recalcitrant Dermatomyositis Treated With Anifrolumab |
| title_sort | recalcitrant dermatomyositis treated with anifrolumab |
| url | https://doi.org/10.1002/acr2.11792 |
| work_keys_str_mv | AT shivangchaudhary recalcitrantdermatomyositistreatedwithanifrolumab AT meghanbaumer recalcitrantdermatomyositistreatedwithanifrolumab AT lauraupton recalcitrantdermatomyositistreatedwithanifrolumab AT samanthaong recalcitrantdermatomyositistreatedwithanifrolumab AT kristinsmith recalcitrantdermatomyositistreatedwithanifrolumab AT danielwest recalcitrantdermatomyositistreatedwithanifrolumab AT adamkilian recalcitrantdermatomyositistreatedwithanifrolumab |